Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834

被引：56

作者：

Young, Wendy B. ^{[1
]}

Barbosa, James ^{[2
]}

Blomgren, Peter ^{[2
]}

Bremer, Meire C. ^{[1
]}

Crawford, James J. ^{[1
]}

Dambach, Donna ^{[1
]}

Gallion, Steve

Hymowitz, Sarah G. ^{[1
]}

Kropf, Jeffrey E. ^{[2
]}

Lee, Seung H. ^{[2
]}

Liu, Lichuan ^{[1
]}

Lubach, Joseph W. ^{[1
]}

Macaluso, Jen ^{[2
]}

Maciejewski, Pat ^{[2
]}

Maurer, Brigitte ^{[1
]}

Mitchell, Scott A. ^{[2
]}

Ortwine, Daniel F. ^{[1
]}

Di Paolo, Julie ^{[2
]}

Reif, Karin ^{[1
]}

Scheerens, Heleen ^{[1
]}

Schmitt, Aaron ^{[2
]}

Sowell, C. Gregory ^{[1
]}

Wang, Xiaojing ^{[1
]}

Wong, Harvey ^{[1
]}

Xiong, Jin-Ming ^{[2
]}

Xu, Jianjun ^{[2
]}

Zhao, Zhongdong ^{[2
]}

Currie, Kevin S. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Gilead Sci Inc, Branford, CT 06405 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 06期

关键词：

Kinase inhibitor; Bruton's tyrosine kinase; Btk; Rheumatoid arthritis; GDC-0834; Amide hydrolysis; Single dose IND; COLLAGEN-INDUCED ARTHRITIS; B-CELL; INFLAMMATORY DISEASES; IBRUTINIB;

D O I：

10.1016/j.bmcl.2015.01.032

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, but with much improved PK in preclinical animal models. Structure based design efforts drove this work as modifications to 1 were investigated at both the solvent exposed region as well as 'H3 binding pocket'. However, in vitro metabolic evaluation of 2 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclinical species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics. Due to its promising potency, selectivity, and preclinical efficacy, a single dose IND was filed and 2 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics. In human, 2 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure. This information informed the back-up program and discovery of improved inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：1333 / 1337

页数：5

共 50 条

[21] Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases [J].

Shi, Qing ;

Tebben, Andrew ;

Dyckman, Alaric J. ;

Li, Hedy ;

Liu, Chunjian ;

Lin, James ;

Spergel, Steve ;

Burke, James R. ;

McIntyre, Kim W. ;

Olini, Gilbert C. ;

Strnad, Joann ;

Surti, Neha ;

Muckelbauer, Jodi K. ;

Chang, Chiehying ;

An, Yongmi ;

Cheng, Lin ;

Ruan, Qian ;

Leftheris, Katerina ;

Carter, Percy H. ;

Tino, Joseph ;

De Lucca, George V. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (09) :2206-2211

[22] Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors [J].

Zhao, Xinge ;

Huang, Wei ;

Wang, Yazhou ;

Xin, Minhang ;

Jin, Qiu ;

Cai, Jianfeng ;

Tang, Feng ;

Zhao, Yong ;

Xiang, Hua .

BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (15) :4344-4353

[23] Bruton's Tyrosine Kinase and Its Isoforms in Cancer [J].

Wang, Xianhui ;

Kokabee, Leila ;

Kokabee, Mostafa ;

Conklin, Douglas S. .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9

[24] A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis [J].

Airas, Laura ;

Bermel, Robert A. ;

Chitnis, Tanuja ;

Hartung, Hans-Peter ;

Nakahara, Jin ;

Stuve, Olaf ;

Williams, Mitzi J. ;

Kieseier, Bernd C. ;

Wiendl, Heinz .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17

[25] Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials [J].

Burger, Jan A. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (01) :44-49

[26] Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials [J].

Jan A. Burger .

Current Hematologic Malignancy Reports, 2014, 9 :44-49

[27] Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors [J].

Zou, Yi ;

Xiao, Jianhu ;

Tu, Zhengchao ;

Zhang, Yingyi ;

Yao, Kun ;

Luo, Minghao ;

Ding, Ke ;

Zhang, Yihua ;

Lai, Yisheng .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (13) :3052-3059

[28] Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies [J].

Campbell, Robert ;

Chong, Geoffrey ;

Hawkes, Eliza A. .

JOURNAL OF CLINICAL MEDICINE, 2018, 7 (04)

[29] Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series [J].

Liu, Qingjie ;

Batt, Douglas G. ;

Chaudhry, Charu ;

Lippy, Jonathan S. ;

Pattoli, Mark A. ;

Surti, Neha ;

Xu, Songmei ;

Carter, Percy H. ;

Burke, James R. ;

Tino, Joseph A. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (18) :3080-3084

[30] Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor [J].

Herman, Ann E. ;

Chinn, Leslie W. ;

Kotwal, Shweta G. ;

Murray, Elaine R. ;

Zhao, Rui ;

Florero, Marilyn ;

Lin, Alyse ;

Moein, Anita ;

Wang, Rena ;

Bremer, Meire ;

Kokubu, Serika ;

Serone, Adrian P. ;

Hanze, Eva L. ;

Viberg, Anders ;

Morimoto, Alyssa M. ;

Winter, Helen R. ;

Katsumoto, Tamiko R. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (06) :1020-1028

← 1 2 3 4 5 →